From www.aicd.com.au: Dual listings allow companies to access new pools of capital and enhance their market profile, but they also bring increased complexity and costs.

Companies like Mesoblast and Immuron have successfully raised significant funds through secondary listings on Nasdaq, benefiting from specialized investor interest.

However, the dual listing strategy requires careful consideration of the potential impacts on liquidity, administration, and compliance with varying regulations in different markets.